Table 2: Cell viability IC50 values and drug interaction measurements.
(a) Cell viability

Sarcoma type/cell lineVorinostatEtoposideSorafenibTopotecanDasatinibMK-2206Triciribine
IC50 (µM)SEMn IC50 (µM)SEMn IC50 (µM)SEMn IC50 (nM)SEMn IC50 (µM)SEMn IC50 (µM)SEMn IC50 (µM)SEMn

Ewing
 A-673 1.50.4632.50.926164.956.21.711157.68
 RD-ES 0.5211.50.55226.51.726.81.715122.4137.30.62286.32.826
 SK-ES-1 1.10.1780.470.071216.91.04421522111.5194.30.4141154.211
Osteosarcoma
 MNNG HOS4.31.245.62.0158.00.713310140205.80.77229.20.554069273
 U2-0S1.60.2586.81.1144.90.7521905676.40.7619110.7229195.011
Rhabdomyosarcoma
 A-204 2.20.3883.51.0222.61.73649.4264.21.2137.00.9130185.013
Fibrosarcoma
 HT-1080 2.80.2387.42.024400200148.60.9623110.5830142.513
Leiomyosarcoma
 SK-LMS-1 2.90.4564.81.1148015217.80.99197.70.60308.01.726
 SK-UT-1 3.40.5172.51.222350220219.91.1206.90.564230193
Liposarcoma
 SW-872 2.50.4172.90.84217327214.60.72237.90.5741183.67

(b) Drug interaction measurements

Sarcoma type/cell lineVorinostat and etoposideSorafenib and topotecanDasatinib and MK-2206Dasatinib and triciribine
CI75CI95CISEM EOHSAneg log ValCI75CI95CISEM EOHSAneg log ValCI75CI95CISEM EOHSAneg log ValCI75CI95CISEM EOHSAneg log Val

Ewing
 A-6730.340.340.340.0720.234.70
 RD-ES 1.001.191.100.0720.0461.120.180.180.180.0320.234.400.190.170.180.0830.284.71
 SK-ES-1 1.100.931.010.1030.101.671.581.751.660.3530.0762.240.170.170.170.0730.214.340.390.380.390.0120.188.85
Osteosarcoma
 MNNG HOS 0.780.950.860.2730.081.620.0220.0030.01110.174.10
 U2-OS0.580.530.550.0250.123.980.580.490.530.2820.0601.040.380.540.460.0530.183.720.100.030.0610.367.94
Rhabdoid
 A-204 0.851.200.990.2050.092.580.611.290.910.3230.0882.410.150.140.1410.384.49
Leiomyosarcoma
 SK-LMS-1 0.690.680.670.1030.092.230.310.340.320.0330.213.690.240.230.240.0530.274.61
 SK-UT-1 0.730.680.700.1730.115.390.120.120.120.1020.277.090.280.250.2710.183.82
Liposarcoma
 SW-872 0.530.380.450.1530.193.000.201.140.540.2440.153.96
Fibrosarcoma
 HT-1080 0.230.160.190.0450.242.790.390.760.570.1730.182.87